{"id":"amonafide-l-malate","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Myelosuppression"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL2104952","moleculeType":"Small molecule","molecularWeight":"417.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Amonafide L-Malate works by binding to the DNA minor groove, which prevents the progression of DNA replication and transcription. This leads to the induction of apoptosis in rapidly dividing cancer cells. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of topoisomerase II and the induction of DNA damage.","oneSentence":"Amonafide L-Malate is a quinazoline derivative that intercalates DNA, thereby inhibiting DNA synthesis and inducing apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:58.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT01066494","phase":"PHASE2","title":"A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)","status":"UNKNOWN","sponsor":"Antisoma Research","startDate":"2010-01","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT00715637","phase":"PHASE3","title":"Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study","status":"UNKNOWN","sponsor":"Antisoma Research","startDate":"2007-06","conditions":"Secondary Acute Myeloid Leukemia (Secondary AML, sAML)","enrollment":420},{"nctId":"NCT00087854","phase":"PHASE1, PHASE2","title":"Study of Individualized Amonafide to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Xanthus Pharmaceuticals, Inc.","startDate":"2004-03","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT00273884","phase":"PHASE2","title":"Amonafide in Combination With Cytarabine in Secondary AML","status":"COMPLETED","sponsor":"Xanthus Pharmaceuticals, Inc.","startDate":"2005-08","conditions":"Acute Myeloid Leukemia","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Amonafide L-Malate","genericName":"Amonafide L-Malate","companyName":"Xanthus Pharmaceuticals, Inc.","companyId":"xanthus-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amonafide L-Malate is a quinazoline derivative that intercalates DNA, thereby inhibiting DNA synthesis and inducing apoptosis in cancer cells. Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}